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Abstract
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential
thrombocythaemia and primary myelofibrosis, originate from a stem cell-derived clonal myeloproliferation that manifests itself with vari-
able haematopoietic cell lineage involvement; they are characterized by a high degree of similarities and the chance to transform each
to the other and to evolve into acute leukaemia. Their molecular pathogenesis has been associated with recurrent acquired mutations in
janus kinase 2 (JAK2) and myeloproliferative leukemia virus oncogene (MPL). These discoveries have simplified the diagnostic approach
and provided a number of clues to understanding the phenotypic expression of MPNs; furthermore, they represented a framework for
developing and/or testing in clinical trials small molecules acting as tyrosine kinase inhibitors. On the other hand, evidence of abnormal
epigenetic gene regulation as a mechanism potentially contributing to the pathogenesis and the phenotypic diversity of MPNs is still
scanty; however, study of epigenetics in MPNs represents an active field of research. The first clinical trials with epigenetic drugs have
been completed recently, whereas others are still ongoing; results have been variable and at present do not allow any firm conclusion.
Novel basic and translational information concerning epigenetic gene regulation in MPNs and the perspectives for therapy will be criti-
cally addressed in this review.
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The myeloproliferative neoplasms
According to the 2008 classification system for haematologic
malignancies from the World Health Organization (WHO) the cate-
gory of myeloproliferative neoplasms (MPNs) includes chronic
myelogenous leukaemia (CML, which is marked by the
t(9;22)(q34;q11) translocation-BCR/ABL rearrangement), poly-
cythaemia vera (PV), essential thrombocythaemia (ET), primary
myelofibrosis (PMF), mastocytosis, chronic eosinophilic
leukaemia not otherwise specified (CEL-NOS), chronic neutrophilic
leukaemia (CNL) and ‘MPN, unclassifiable’ [1]. In this review, we
will focus only on the so-called ‘classic’ MPNs, that is PV, ET and
PMF, with reference to other MPNs if appropriate. These disorders,
whose original identification is credited to W. Dameshek in 1951
[2], share a number of common features [3] that include: the ori-
gin in a multi-potent haematopoietic stem cell; an expanded pool
of mature cells and precursors with preserved cellular maturation;
discrete overlap in the clinical phenotype, and the possibility to
transform each into the other or to evolve to acute myeloid
leukaemia (AML) [4]. A revision [5] to the previous 2001 WHO
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classification has been prompted by discoveries in 2005 of recur-
rent mutations in janus kinase 2 (JAK2; JAK2V617F) [6–9] or MPL
(MPLW515L/K) [10] and of JAK2 exon 12 mutations [11], which
have rapidly improved knowledge on pathogenetic aspects of the
diseases and simplified the diagnostic approach. Several recent
reviews on these issues have been published [12–16].
PV and ET are relatively indolent disorders [17] that result in a
modest reduction of survival, particularly evident after the first
decade far from diagnosis; on the contrary, PMF has a more
severe course with median survival of about 5 years, although
younger patients with low-risk disease may experience survival in
excess of 10 years. The most clinically relevant events that occur
during the course of PV or ET are arterial and venous thrombosis,
haemorrhage, evolution to post-polycythemic or post-thrombo-
cythemic myelofibrosis [18] and transformation to AML [19–21].
In the observational arm of the European collaborative study on
low-dose aspirin in PV (ECLAP), the largest study available that
included 1638 patients, thrombotic events and transformation to
myelofibrosis or AML were responsible for 41% and 13% of all
fatalities [20, 22]; accordingly, patients with PV or ET are currently
stratified according to the risk of cardiovascular events [23]. Age
older than 60 years and/or a previous history of thrombosis allow
to identify a category of patients with ‘high-risk’ disease who,
unlike the others, are candidate to cytoreductive therapy [20, 24,
25]; in addition, low-dose aspirin is recommended in all PV
patients independent of risk category [26] as well as in most
patients with ET. The most commonly used cytoreductive agent is
hydroxyurea (HU) because of its proven effectiveness in reducing
life-threatening cardiovascular events [27–29]. However, the
safety of HU as concerns the risk of transformation to acute
leukaemia is still an unsettled issue [16, 23], although most evi-
dence are against a significant raised rate of occurrence [22]. On
the other hand, the risk of leukaemia was significantly increased in
patients who received other chemotherapeutics in combination or
in sequence with HU [22, 30], or who were treated with radiophos-
phorus [22] or chlorambucil [31].
In patients with PMF, the major causes of death are repre-
sented by portal hypertension or hepatic/splenoportal thrombosis
and their complications, heart failure, infections, pulmonary
hypertension, bleeding, thromboses and leukaemia transforma-
tion [21, 32]. Patients with low- and high-risk disease with signif-
icantly different survival can be identified based on prognostic
scoring systems [33, 34]. Stratification according to the risk is
particularly relevant for younger patients who can potentially
exploit the curative effect of allogeneic haematopoietic stem cell
transplantation [35]; in fact, conventional drug therapy does not
appreciably modify the course of disease and it is reserved to
patients who present anaemia or have symptomatic splenomegaly.
In summary, therapy for MPNs is mainly employed to counter-
act signs and symptoms of myeloproliferation, to prevent throm-
bosis and for the treatment of anaemia or thrombocytopenia in
myelofibrosis; however, with the possible exception of interferon-
(IFN-) in PV according to recent reports [36–38], none of the
agents currently employed proved able to significantly affect the
abnormally proliferating myeloid clone.
The molecular pathogenesis of MPN
The first recurrent molecular abnormalities in the classic MPN have
been identified only a few years ago. The JAK2V617F mutation, as
a result of a G to T nucleotide shift at nt 1849 in exon 14, is located
in the tyrosine kinase-like domain-2 (JH2) pseudo-kinase domain
of JAK2 and likely results in the loss of auto-inhibitory control
and/or cytokine-induced hyper-activation of JAK2 [39]. Expression
of V617F-mutated allele in cytokine-dependent cell lines conferred
cytokine independence and cytokine hypersensitivity through the
constitutive activation of signal transducers and activators of tran-
scription-5 (STAT5), v-akt murine thymoma viral oncogene
homolog 1 (AKT) and extracellular signal-regulated kinase (ERK)-
dependent pathways [13, 40]; in addition, mice transplanted with
marrow cells transduced with a retrovirus expressing JAK2V617F
invariably developed erythrocytosis [6, 41–44] eventually associ-
ated with leucocytosis, splenomegaly and later changes suggestive
of transformation to post-polycythemic myelofibrosis [41–44].
More recently, transgenic mice presenting an expression of mutated
allele lower than wild-type one have been generated, and found to
develop an ET-like phenotype [45, 46]; overall these data suggest
that the JAK2V617F mutation is an integral component of the
myeloproliferative process that underlies the different classic MPNs.
The frequency of JAK2V617F mutation is estimated at over 95% in
PV, 60% in ET or PMF [47, 48] as well as 50% in patients with
the infrequent entity ‘refractory anaemia with ringed sideroblasts
and thrombocytosis’ (RARS-T) [49, 50]. The mutation can be
found on one or both alleles (homozygosity) as a result of a mitotic
recombination process that occurs in most patients with PV or
PMF and a minority only of ET [6, 8, 9]. Additional complex muta-
tions, deletions or insertions have been detected in exon 12 of
JAK2 and are usually associated with clinical features typical of a
JAK2V617F-negative PV or idiopathic erythrocytosis [11, 51].
Finally, somatic mutations involving codon 515 of MPL [10, 52]
(the receptor for thrombopoietin, named after myeloproliferative
leukaemia virus oncogene homologue) are located in the cytoplas-
mic juxtamembrane portion; the commonest are represented by
W515L (a tryptophan to leucine substitution) and W515K (a tryp-
tophan to lysine substitution). They are detected in ≅10% of
patients with PMF [10, 52, 53] or ≅8% of JAK2V617F-negative ET
[54, 55]. MPLW515L introduction in cell lines resulted in a
cytokine-independent growth and hyper-sensitivity to thrombopoi-
etin [56], while its expression in a transplant murine model caused
a rapidly fatal disease reminiscent of PMF [10]. Interestingly, in
some patients multiple MPL mutations or the coexistence with
JAK2V617F allele have been reported [53, 55, 57].
There are some hypotheses to explain the association of
JAK2V617F mutation with at least three different clinical pheno-
types [58, 59]. One is the so-called ‘gene-dosage’ hypothesis that
suggests that disease-associated phenotypes are the result of the
relative proportion of mutated and wild-type allele, with ET (the
lowest) and PV or post-polycythemic myelofibrosis (the highest)
located at the opposite of the spectrum. Second, JAK2V617F 
may not be the initial clonogenic event in MPNs and a predicted
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‘pre-JAK2’ mutated cell exists as the founder of clonal
haematopoiesis that acquires JAK2 mutation as a secondary event
[60, 61]. This hypothesis is also supported by recent findings of
mutations in ten-eleven translocation-2 (TET-2) reported by the
Vainchenker’s group [62]. Finally, there can be a role also for inher-
ited host genetic characteristics, such as the single nucleotide
polymorphisms (SNPs) in JAK2 that have been associated prefer-
entially with the diagnosis of PV rather than the other MPNs [63],
or generic host characteristics (gender, iron availability, hormones).
Furthermore, it can be suggested that subtle changes in gene
expression because of epigenetic regulation also contribute, in a
non-mutually exclusive but rather cooperative manner with the
previous events, to the MPN phenotypic variability. After all, it is a
matter of speculation if PV, ET and PMF are separate diseases or
different presentations/different phases of a unique disease [64].
Epigenetic events in cancer
Epigenetic changes are cell-heritable, potentially modifiable abnor-
malities that affect gene expression [65]. There are two main clas-
sic mechanisms that control gene expression through epigenetic
changes: DNA methylation and acetylation of histone proteins.
However, although most efforts in understanding epigenetics and
in developing epigenetic therapy have been directed against DNA
methylation and histone acetylation, additional epigenetic alter-
ations are probably at least as relevant as the previous two; these
include histone methylation that can be associated either with
transcriptional activation or repression [66, 67], or other key mol-
ecules involved in the regulation of gene expression, such as
micro-ribonucleic acids (microRNAs) [68] (Fig. 1).
DNA methylation occurs when a cytosine residue at a ‘CpG’
site, that is a cytosine that precedes a guanine, becomes cova-
lently bound with a methyl group at the 5-carbon position, a reac-
tion that is catalyzed by a family of DNA methyltransferases. There
are CpG dinucleotide-rich regions in specific locations along the
genome that are called ‘CpG islands’, usually at the 5’ regulatory
region of many genes; when there is a high degree of methylation
in this CpG-rich regions of promoter, the gene cannot be efficiently
transcribed. Promoter methylation is a normal process for the
orchestrated control of transcriptional activity during development
and cell-lineage specification, but it also contributes substantially
to tumourigenesis. Hypermethylation at specific gene loci, partic-
ularly of tumour-suppressor genes, and global hypomethylation of
genomic DNA, as well as inactivation of microRNA genes by DNA
methylation [69, 70], are all common findings in human cancer
cells [69–71]. Reduced global methylation in cancer cells is
mainly because hypomethylation of DNA repetitive sequences,
coding regions and introns, particularly in areas of the genome
characterized by a low content of coding genes, and increases fur-
ther during cancer progression [72]. Mitotic recombination and
chromosomal rearrangements can be facilitated by global DNA
hypomethylation [73], as suggested by the observation that mice
carrying a diffuse genome hypomethylation as a result of a
 hypomorphic DNA methyltransferase 1 (DNMT1) allele develop
aggressive T-cell lymphomas associated with a high rate of chro-
mosome 15 trisomy [74] and by the profound structural alter-
ations of chromosome pericentromeric regions in the rare
‘immunodeficiency-centromeric instability-facial anomalies (ICF)’
syndrome (OMIM 242860) caused by germ-line mutations in
DNMT3b [75]. Loss of methylation in normally silent regions of the
genome could also cause the inappropriate expression of genes
normally silenced, including imprinted genes or genes of the inac-
tive X chromosome. On the opposite, abnormal gain in DNA
methylation with aberrant silencing of transcription may occur at
specific gene promoter regions and represents a mechanism for
inactivation of tumour-suppressor genes. Examples are the hyper-
methylation of von Hippel Lindau gene in renal cancers or the cell-
cycle control gene p16 in many types of cancer [76]. A tumour
type-specific ‘hypermethyloma’ corresponds to the profile of CpG
island hypermethylation in both sporadic cancers and inherited
cancer syndromes; in the latter, occurring of abnormal methyla-
tion can be considered as the second lesion in a multiple-hit
tumourigenesis model [77]. The mechanistic relevance of gene
promoter hypermethylation in genes that do not apparently func-
tion as tumour-suppressor genes is a matter of discussion, but it
is very likely that these might contribute to the phenotypic diver-
sity of cancer; for example, promoter hypermethylation-induced
silencing of tissue inhibitor of metalloproteinases-3 (TIMP-3),
which encodes for a protease inhibitor, may result in facilitation of
tumour cell dissemination [78].
Hypermethylation of CpG islands in gene promoter regions is
often associated with specific modification of histones; however,
in some instances gene silencing in association with modified his-
tone profile has been observed even in the absence of CpG island
hypermethylation. As a matter of fact, differential chemical modi-
fications of histone tail, that is acetylation and methylation, can
affect not only DNA replication and DNA repair, but also gene tran-
scription. Acetylation of histones is accomplished by the compet-
ing activities of histone acetyl transferase (HAT) and histone
deacetylases (HDAC). Acetylated histones have a reduced interac-
tion with the negatively charged DNA, because of lowered positive
charge of lysine residue in the presence of acetyl group, and on
turn this facilitates the interaction of transcription factors to con-
sensus target sequences on gene promoter [79]. However,
although drugs acting as HDAC inhibitors can facilitate the re-
expression of genes whose promoter sequence is not hyperme-
thylated, they are generally little or not effective in contrasting
gene silencing when gene regulatory sequences are hypermethy-
lated. A sequential treatment scheduling, which involves exposure
to a demethylating agent  followed by HDAC inhibitors, usually
results in synergistic re-expression of silenced genes, at least in
most culture conditions [80].
Mature microRNAs are short (19–25 nucleotides) RNAs origi-
nated from the cleavage of a 70–100 nucleotide hairpin precursor
(pre-microRNA) that hybridize to complementary mRNA targets
and either lead to their degradation or prevent their translation of
corresponding protein, at least in part depending on the degree of
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nucleotide complementarity [81–83]. Expression of microRNAs is
tissue and developmental stage specific, and as such they are
involved in normal cell homeostasis; however, they are also being
increasingly recognized as a new class of genes that are altered in
human malignancies and can eventually function as oncogenes
(onco-microRNAs) [84]. On the contrary, some microRNAs may
have tumour-suppressor function, as argue by their down-regula-
tion in certain tumours; for example let-7 and mir15/mir-16
 control the expression of ras sarcoma (RAS) [85] and B cell lym-
phoma gene-2 (BCL-2) [86], respectively. A role of microRNAs in
haematologic malignancies is supported by recent studies, and
they have also been proposed as prognostic markers and thera-
peutic targets in chronic and acute leukaemias [87]. However, the
fine mechanisms that tune the transcriptional expression of
microRNAs are still largely unknown, and may depend on the bind-
ing of transcription factors to promoter [88, 89] as well as on
 differential methylation of the microRNA gene or of putative 5’ reg-
ulatory sequences [90, 91]. In turn, recent evidence suggests that
miRNAs could also play important roles in controlling DNA methy-
lation and histone modification [92].
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Fig. 1 The figure schematizes the main epigenetic mechanisms involved in regulation of gene expression, that is DNA methylation, histone modifications
and non-coding small RNAs, the microRNAs. These mechanisms appear to be interconnected on multiple levels. DNA methylation occurs almost exclu-
sively on cytosine preceding guanine pairs in short DNA regions characterized by more than 55% of CG (the ‘CpG islands’), and is achieved by the addition
of a methyl group to 5’ position of a cytosine ring mediated by DNMTs. Most CpG ‘islands’ are located in gene promoter regions and are normally un-methy-
lated, unlike the sporadic CpG sites in the rest of the genome that are methylated. Methylation of CpG islands in promoter regions is often associated with
gene silencing. Histone modifications result in condensed DNA. H3-H4 tetramer and two H2A-H2B dimmers form the octamer that constitutes the core his-
tones around which two helical turns of DNA wasp. Acetylation is associated with active gene transcription, whereas other histone modifications correspond
to condensed and inactive chromatin. In fact, methylation of H3 at K4 is closely linked to transcriptional activation whereas methylation of H3 at K9 or K27
is associated with transcriptional repression. Whereas classical epigenetics mechanisms regulate gene expression at the transcriptional level, microRNAs
function mainly at the post-transcriptional level. The miRNA guides RISC to mRNA target and then miRISC cleaves, degrades or suppress translation of the
target mRNA depending on the degree of complementary between miRNA and mRNA. Me, methyl group; C, cytosine; G, guanosine; Ac, acetyl group; Met,
methylation; K, lysine; miRISC, RNA-induced silencing complex (RISC) that incorporates the guide strand (miRNA) and the target mRNA.
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Epigenetic events in MPN
Studies on epigenetic gene regulation in MPNs are still scanty and
have been focused on single genes credited as being potentially
involved in the pathogenesis of these disorders. Table 1 lists pub-
lished studies that reported an analysis of gene methylation in
cells from MPN patients; in most instances, no evidence for
abnormal hypermethylation of the genes was found, while some
notable exceptions will be discussed briefly here. Preliminary
results of genome-wide methylation analysis pointed to a high rate
of gene methylation in PMF patients [93]; furthermore, a unique
profile of enhanced histone deacetylase enzyme activity has been
described in these patients  [94].
Much attention has been devoted to the study of gene methy-
lation status of suppressors of cytokine signalling family proteins
(SOCS), particularly SOCS1 and SOCS3. These proteins are rap-
idly induced following receptor binding of several cytokines,
including erythropoietin, interleukin-3 (IL-3) and GM-CSF; in turn,
they function as negative regulators of the JAK/STAT pathway by
© 2009 The Authors
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Table 1 Abnormal gene methylation in MPNs
Gene symbol Gene nomenclature Methy* N/Y Details Reference
ABL1
V-abl Abelson murine leukaemia viral oncogene
homologue-1
Y Less than 10% of patients [168]
CALCA Calcitonin Y Mainly in PMF [169]
p14 ARF Cyclin-dependent kinase inhibitor 2A, isoform 4 N [108, 170]
p15 Cyclin-dependent kinase inhibitor 2b
p16 Cyclin-dependent kinase inhibitor 2a
Rb Retinoblastoma-associated protein
hMLH1 DNA mismatch repair protein Mlh1
hMSH2 DNA mismatch repair protein Mlh2
APC Adenomatous polyposis coli protein
DAPK1 Death-associated protein kinase 1
p15 Cyclin-dependent kinase inhibitor 2b Y
In 20–40% of PMF patients in
leukaemic transformation
[171]
p16 Cyclin-dependent kinase inhibitor 2a
NPM1 Nuclephosmin N [172]
CDH1 Epithelial cadherin N [108]
p73 p53-like transcription factor
TIMP-2/-3 Tissue inhibitors of matrix metalloproteinases
MGTM O6-methylguanine DNA transferase
RASSF1A RAS effector homologue 1
SHP-1 SH2 domain containing tyrosine phosphatase 
RARB Retinoic acid receptor- Y Putative oncosuppressor [173]
N [108]
TGFbeta RII Transforming factor- receptor II N [174, 175]
PRV-1 CD177, polycythaemia rubra vera protein 1 Y [110]
CXCR4 Stromal cell-derived factor 1 receptor Y [114, 115]
SOCS1 Suppressor of cytokine signalling 1 N
Variable results possibly because of
different regions analysed 
[101, 103, 108]
Y
SOCS3 Suppressor of cytokine signaling 3 Y
Mainly in PMF. Different promoter
regions analyzed in different studies
[101–103]
*Indicates whether significant hypermethylation of gene promoter was found.
N refers to studies where 10% of cases presented evidence of gene promoter hypermethylation.
1442
reducing the phosphorylation of both JAK and STAT, preventing
STAT dimerization and its translocation to the nucleus, and finally
resulting in reduced transcription of target genes [95].
Interestingly, the negative regulatory function of SOCS3 may be
lost in MPN cells, because SOCS3 was actually found to be pro-
moting, rather than reducing, the proliferation of cells expressing
JAK2V617F, possibly through a JAK2V617F-induced enhanced
phosphorylation of the protein itself [96]. Previous data indicated
that SOCS1 can function as a tumour-suppressor gene and its
down-regulation contributes to tumour progression [97]; SOCS1
down-regulation as a result of gene hypermethylation was
detected in several neoplasia, including CML [98] where it corre-
lated with poor cytogenetic response to IFN- [99]. Similarly,
hypermethylation of SOCS3 promoter with reduced protein levels
was described in several solid tumours. Hypermethylation of
SOCS3 in MPNs has been detected in several studies [100–103],
particularly in PMF patients [103]; unexplainably, promoter
methylation did not correlate with a low level of transcription,
although a trend towards an association between SOCS3 methyla-
tion and reduced protein was observed in the subgroup of
JAK2V617F-negative patients [101]. Of interest, SOCS3 hyperme-
thylation was also detected in six ET females negative for the
JAK2V617F or MPLW515L/K mutation who had clonal
haematopoiesis [100]. Results concerning SOCS1 methylation
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Table 2 Compounds acting as epigenetic drugs that are under study for the treatment of human cancer
Drug class Drug name
Clinical 
development 
stage
Diseases Notes/Company
Histone deacethylase inhibitors
Short-chain fatty acids
Butyrate/
phenylbutyrate
Phase I Refractory solid tumours
Valproic acid Phase I/II Advanced solid tumours, MDS, refractory AML, CLL
Approved for seizures Abbott
Lab. (Abbott Park, IL, USA)
Cyclic tetrapeptides
Depsipeptide Phase I/III Refractory solid tumours, CLL, AML, CTCL, TCL 
Gloucester Pharm. Inc.
(Cambridge, MA, USA)
Hydroxamic acids
SAHA Phase I
Refractory solid tumours, NHD, HD, ML, MM, AML,
MDS, MPNs, CML, CLL, CTCL, DLBCL, MCL, 
NK-TCL, GvHD
Approved for CTCL 
(Vorinostat) Merck & Co (North
Wales, PA, USA)
LBH589/LAQ824 Phase I/II
Refractory solid tumours TCL, CTCL, HD, AML, MDS,
CML, ALL, MM
Novartis Corp. (Basel,
Switzerland)
PXD101 Phase I/II Refractory solid tumours, DLBCL, CLL, MM
Curagen Corp. (Branford, CT,
USA), TopoTarget (Copenhagen,
Denmark)
ITF2357 Phase I/II MPNs, HD, CLL Italfarmaco (Milan, Italy)
Amides
MS-275 Phase I/III Refractory solid tumours, Lymphomas, AML, MDS, CML Bayer Schering (Berlin, Germany)
MGCD0103 Phase II Advanced solid tumours, NHD Methylgene Inc. (Quebec, Canada)
CI-994 Phase II Advanced solid tumours Pfizer Inc. (New York, NY, USA)
DNMT inhibitors
Azacitidine Phase I/II
MDS, AML;, MM, CML, LLC, NK-TCL, FL, advanced
solid tumours
CELGENE Corp. 
(Summit, NJ, USA)
Decitabine Phase I/II/III MDS, AML, MPNs, CML, ALL, advanced solid tumours MDS Pharma (Lincoln, NE, USA)
Information derived from the National Cancer Institute web site (http://www.cancer.gov/search/SearchClinicalTrialsAdvanced.aspx).
MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia; MPNs, myeloproliferative neoplasms; CML, chronic myelogenous leukaemia; CLL,
chronic lymphoid leukaemia; ALL, acute lymphoblastic leukaemia; HD, Hodgkin disease; FL, follicular lymphoma; NHD, non-Hodgkin disease; TCL,
T-cell lymphoma; MM, multiple myeloma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; NK-TCL, natural killer T-cell lym-
phoma; CTCL, cutaneous T-cell lymphoma; GvHD, graft versus host disease.
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have been more conflicting, and may largely depend on the
genomic region employed for methylation status analysis. SOCS1
hypermethylation has been variably reported in AML [104, 105],
CML [98, 106] and myelodysplastic syndromes [107]. Conversely,
a minority only of MPN patients were reported to have SOCS1
hypermethylation [102, 108].
Abnormally high levels of the polycythaemia rubra vera-1
(PRV-1) gene, encoding for the GPI-linked CD177 protein, are
expressed by MPN neutrophils [109], although the levels of
mature protein do not differ at all compared to control neutrophils.
PRV-1 expression in PV or ET patients has been associated with a
reduced level of methylation of CpG sites located close to the tran-
scription start site [110], and decitabine decreased PRV-1 methy-
lation and increased PRV-1 mRNA levels in the KG1 and KG1a
leukaemic cell lines. Interestingly, methylation of PRV-1 correlated
inversely with the presence of JAK2V617F mutation, and the
degree of methylation at CpG 30 (the most conserved site of
methylation in PRV-1 up-stream sequence) showed a significant
inverse correlation with JAK2V617F allele burden [110].
The constitutive mobilization of haematopoietic stem CD34
cells in the peripheral blood is a characteristic finding in patients
with PMF [111]; the abnormally high number of circulating CD34
cells has been associated with reduced membrane expression of 
C-X-C chemokine receptor type 4 (CXCR4), which is the receptor
for stromal-derived factor-1 (SDF-1), the major chemoattractant
for normal haematopoietic stem and progenitor cells [112, 113]. It
has been found that CXCR4 is epigenetically regulated and that the
extent of methylation of unique CpG islands of the promoter is
abnormally high in PMF compared to control cells and is correlated
with the protein content on cell membrane [114]. A short-term
treatment with 5-Aza reduced promoter methylation, increased
membrane expression of CXCR4 and resulted in improved migra-
tion of CD34 cells in response to SDF-1 in vitro [114]. Similar
findings have been reported after long-term incubation of PMF
CD34 cells exposed to 5-Aza followed by trichostain A [115], and
this treatment corrected bone marrow seeding of treated cells once
infused in non-obese diabetic severe combined immunodeficiency
(NOD/SCID) mice [116]. Importantly, it was shown that this com-
bined treatment also caused reduced proliferation of PMF CD34
(as opposite to normal cells) and resulted in significant reduction
in the proportion of JAK2V617F mutated cells and of mutated cells
harbouring the mutation in an homozygous status, suggesting a
preferential effect on cells of the mutated clone [115].
How somatic mutations and abnormal epigenetic gene regula-
tion interact in the pathophysiology of MPNs is largely unknown,
but recent data lend support to suggesting a functional link between
the increased tyrosine kinase activity of JAK2 and epigenetically reg-
ulated genes. Over-activation of the Hopscotch gene, a JAK homo-
logue gene in Drosophila Melanogaster, led to a global disruption of
heterochromatic gene silencing and promoted tumourigenesis, indi-
cating that the JAK/STAT pathway normally regulates cellular epige-
netic status [117]. Consistently, binding of STAT3 to promoter and
enhancer sequences of the DNA methyltransferase 1 gene (DNMT1)
in malignant T-cell lymphoma cells resulted in induction of DNMT1
expression, which in turn supported STAT3 persistent activation
[118]. Overall, these data provided a framework for supporting a
direct involvement of aberrant JAK/STAT signalling in epigenetic
silencing of genes important for cellular transformation.
Finally, unique expression profiles of microRNAs in granulo-
cytes [119] or other mature haematopoietic cell sub-populations
[120, 121] from MPN patients have been characterized; a general
down-regulation of microRNAs was found, as reported in other
cancer cells, with some notable exception of microRNAs that were
overexpressed, some of them in a JAK2V617F-associated manner
[119, 120]. However, information about validated gene targets and
the mechanisms underlying differential expression of microRNA in
MPNs is still lacking [59].
Drugs for epigenetic therapy
Drugs acting on epigenetic control of gene expression fall into two
broad categories: inhibitors of methyltransferases and histone
deacetylase (HDAC) inhibitors (listed in Table 2). Among them,
those most widely employed are azacytidine, decitabine and
vorinostat. These drugs have been used in phase I trials in patients
with haematological and solid cancers, and several phase II trials
are underway (Table 2). Among myeloid malignancies, most expe-
rience has been collected in patients with myelodysplastic syn-
dromes and AML [122] .
Hypomethylating agents such as azacitidine and decitabine act
by inhibiting DNMT1 and cause DNA hypomethylation leading to
induction of silenced genes involved in cellular differentiation and
proliferation. Although the demethylating effect depends on incor-
poration of the drug into DNA, the cytotoxicity of azacitidine is
additionally as a result of halting of protein synthesis because the
drug is incorporated into RNA as well. Their clinical efficacy in
haematological malignancies has been demonstrated in vitro and
in a series of phase I and II trials. Azacitidine was first approved
by FDA in 2004 for the treatment of myelodyspalstic syndrome
(MDS), based on two phase II [cancer and leukemia group B
(CALGB) 8421 and 8921] and one phase III (CALGB 9221) trials in
which azacitidine at 75 mg/m2/day for 7 days every 28 days used
by continuous intravenous infusion or subcutaneous administra-
tion was compared with the best supportive care. The phase II
 trials recorded complete remission (CR), partial remission (PR)
and haematological improvement (HI) rates of 15%, 2% and 27%,
and of 17%, 0% and 23% in the CALGB 8421 and CALGB 8921,
respectively [123]. A subsequent phase III randomized trial in 191
MDS patients reported an overall response rate of 60% on the
azacitidine arm (CR, 7%) compared with 5% of patients receiving
supportive care; median time to leukaemic transformation or
death was significantly prolonged by azacitidine (21 versus
13 months). A recent re-analysis of the three CALGB trials by
applying WHO classification and International Working Group
(IWG) response criteria confirmed those response figures, with
90% of patients achieving a response by six cycles; however,
whereas quality of life significantly ameliorated, there was no
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improvement in overall survival in the whole patient population or
in the separate classes of risk [124]. The combination of azaciti-
dine with histone deacetylase inhibitors, such as sodium phenyl-
butyrate [125], valproic acid and all-trans retinoic acid [126], has
been explored with little evidence of improvement in patients with
leukaemia or high-risk MDS.
Decitabine was approved by FDA in the 2006 for the treatment
of MDS on the basis of a multi-centre trial of 170 patients with
intermediate-2 and high-risk international prognostic score system
(IPSS) disease, randomized versus best supportive care [127];
overall response rate was 17% (CR 9%, PR 8%) with 13% of
patients achieving HI. The median time to response was 3 months
with a response duration of 10.3 months, although there was no dif-
ference between the two arms in time to AML or death. Significant
activity at low, very well-tolerated, doses was reported [128].
Evidence of partially demethylated epigenotypes, including re-
establishment of normal p15 protein expression early after drug
administration, suggested pharmacologic demethylation as the
therapeutic mechanism of action. Decitabine has been used also in
imatinib-resistant CML [129] or in combination with imatinib in
patients with accelerated or leukaemic-phase CML [130].
Vorinostat, suberoylanilide hydroxamic acid (SAHA), is an
inhibitor of class I and II HDAC enzymes, and promotes cell-cycle
arrest and apoptosis of cancer cells [131]; relevant target genes
have been characterized through gene expression analysis [132].
Vorinostat has received FDA approval for the treatment of pro-
gressive, persistent or recurrent on, or after, two systemic thera-
pies T-cell cutaneous lymphoma [133]. In a phase I/II study,
vorinostat was used to treat 41 patients with leukaemia or MDS
who were relapsed or refractory to previous therapy or who were
not candidate to chemotherapy [134]. Haematologic improve-
ment was observed in 17% of cases including two complete
responses in AML. Evidence of histone H3 acetylation was found
in peripheral blood and bone marrow cells, and down-regulation
of proliferation-associated genes was associated with haemato-
logic improvement [134]. A phase IIa trial with vorinostat 
in patients with lower-risk myelodysplastics syndromes
(NCT00486720) and a phase I/II trial of vorinostat in combination
with azacitidine (NCT00392353) are currently underway; prelimi-
nary results from phase I of the combination trial indicated that
the therapy is safe and well tolerated and appears superior 
to azacitidine alone for time to response, overall response and 
CR rate [135].
The HDAC inhibitory activity of valproic acid (VPA), an anti-
epileptic drug, is known since 2001; VPA induces differentiation
and apoptosis in malignant myeloid cell lines. Clinical activity has
been demonstrated in studies in MDS patients who received VPA
orally on a continuous schedule to maintain a serum concentra-
tion of 50–100 g/ml. The first pilot study reported a 44% over-
all response rate in MDS with a median response duration of 
4 months [136]. In a follow-up study on 122 patients with MSD
and AML an overall response rate of 20% was reported, includ-
ing one CR; a higher percentage of response was observed in
low-risk MDS, according to morphological subtype [137]. VPA
has been used in combination with all-trans retinoic acid in
patients with acute leukaemia, eventually in association with 
cytotoxic therapy, without appreciable or with only minor
improvements [138–140].
ITF2357 is a new synthetic HDAC class I inhibitor that possess
a potent anti-proliferative and pro-apoptotic activity against cells
of AML and multiple myeloma [141]. An intriguing property of
HDAC inhibitors relies on their ability to down-modulate several
soluble cytokines secreted by blood cells as well as from acces-
sory cells of the bone marrow microenvironment [142, 143]. The
autocrine and paracrine secretion of different cytokines may play
an important role for the neoplastic proliferation of myeloid pre-
cursor cells, and possibly represents a relevant target of new anti-
neoplastic drugs. Most strikingly, ITF2357 inhibits production of
IL-6, vascular endothelial growth factor (VEGF) and IFN-, with an
IC50 similar to that required for apoptosis induction of leukaemic
cells (0.25–0.5 M). Despite its in vitro and in vivo anti-tumour
activity, ITF2357 showed little toxicity against normal cells such as
mesenchymal stem cells, hepatocytes and peripheral blood
mononuclear cells (MNCs), and thrombocytopenia and gastro-
intestinal toxicity represent the most common side effects after its
use in normal volunteers and patients [144]. Of note, similarly to
other HDAC inhibitors, ITF2357 induces a significant up-regula-
tion of the cell cycle inhibitor p21.
Because it is predicted that over 30% of human genes are reg-
ulated by microRNAs [145, 146], and miRNAs can function either
as oncosuppressors or oncogenes [147], it is easily anticipated
that miRNAs and anti-miRNA drugs have great potential to be
developed as a novel class of epigenetically active drugs for the
treatment of cancer. Specific knockdown of miRNAs by anti-
miRNA oligonucleotides (‘antagomirs’) has been pursued in vitro
and in vivo. Krutzfeldt and coworkers showed for the first time the
long-lasting and non-toxic silencing generated by intravenously
injected antagomir in mice [148]. Inhibition of miR-122 resulted in
a reduction of cholesterol levels and a decrease in hepatic fatty
acids and cholesterol syntesis in normal mice and in diet-induced
obese mice. Several recent papers have generated intriguing data
concerning the systemic [149, 150] or intra-tumoural injection
[151–153] of antagomiRs, for example in the treatment of
melanoma, neuroblastoma or prostate cancer xenografts, where
sizeable reduction of tumour growth could be ascertained. To the
best of our knowledge, there is no experience in MPNs or other
haematologic disorders.
Epigenetic therapy in MPN
Only a few trials using epigenetically active drugs have been
 completed or are ongoing in the classic MPNs. 5-azacitidine has
been used in patients with refractory/relapsed PMF and post-
 polycythemic/post-thrombocythemic MF in two phase II trials that
differed in the drug scheduling. In the first [154], 34 patients
received 5-Aza at 75 mg/m2 daily for 7 days every 4 weeks 
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subcutaneously (total cycle dose, 525 mg/m2), while in the second
trail, a 5-day weekly schedule (total dose, 375 mg/m2) was
employed in 10 patients [155]. Responses were classified accord-
ing to the International Working Group for Myelofibrosis Research
and Treatment (IWG-MRT) criteria [156]. No patient among those
receiving the reduced dosage schedule achieved even a clinical
improvement, the lowest response according to IWG-MRT criteria;
however, only two of the 10 patients had received more than three
of the six planned cycles of therapy because of toxicity, disease
progression or patient choice. Of note, 75% to 90% of responses
in MDS have been observed between cycles 4 and 6 of therapy,
respectively [124], not dissimilar from the median time of 
5 months that was recorded in the higher-dose trial in MF [154].
In this study, one patient presented a partial response (3%) and
clinical improvement occurred in 21% of the patients; the partial
response was maintained for 22 months whereas median dura-
tion of clinical improvement was 4 months. Neutropenia was the
main adverse effect with grade 3–4 severity in 29% of the patients,
and thrombocytopenia all grades occurred in 9%; grade 3–4  
non-neutropenic infections were reported in 26% of the patients.
A kinetic analysis of global methylation of genomic DNA, meas-
ured according to a long interspersed nucleotide element (LINE)
bisulphite pyrosequencing [157], demonstrated a gradual and sig-
nificant decline of LINE methylation. Although changes in the
extent of methylation were not significantly different between
responders and non-responders, the former presented a trend
towards a more rapid hypomethylating effect.
Preliminary results from a phase II multi-centre study with
decitabine in 21 patients with PMF have been reported [158].
Seven patients (37%) responded, including two with blast phase-
MF; there was one CR, two PR and four HI. Median time to
response was two cycles and median duration of response was 
5 months, with two patients maintaining their responses at 2
and 14 months, respectively. There was a 61% reduction in the
count of circulating CD34 cells i that distinguished responders
from non-responders.
The safety and efficacy of the HDAC inhibitor ITF2357 in the
treatment of patients with PV, ET or MF have been evaluated in a
phase II study. The rationale of the clinical trial derived from
results on the in vitro activity of ITF2357 in cells from PV and ET
patients carrying the JAK2V617F mutation. In these experiments,
it was shown that: (i ) cells carrying the mutated JAK2 are sensi-
tive in colony assays to a 100- to 500-fold lower dose of ITF2357
as compared to cells bearing wild-type JAK2; (ii ) in a classical
endogenous erythroid colony (EEC) assay, ITF2357 promotes the
out-growth of normal colonies over that of JAK2V617F mutated
cells; (iii ) ITF2357 induces down-modulation of JAK2V617F but
not JAK2 wild-type protein in human erythroleukemia (HEL) cells,
and (iv ) that JAK2V617F inhibition takes place at the post-
transcriptional level [159]. ITF2357 was evaluated in PV, ET or MF
patients refractory to hydroxyurea or in younger patients who
were in need of cytoreductive therapy [160]. The drug was given
orally at a starting daily dose of 50 mg b.i.d. that could be esca-
lated to 50 mg t.i.d., in the absence of toxicity. A total of 
26 patients (men/women, 12/14), with a median age of 56 (range
36–70) and a confirmed diagnosis of JAK2V617F-positive PV 
(n 	 12), ET (n 	 1), PMF (n 	 4) or post-polycythemic/post-
thrombocythemic MF (n 	 9) were enrolled in this study. In
patients with PV and ET, ITF2357 was well tolerated when given up
to 50 mg t.i.d. (no Grade 4 toxicity) and the haematologic
response (CRPR) was 50% at 12 weeks and 40% at 24 weeks.
A rapid and sustained improvement of pruritus was observed in
80% and a reduction of splenomegaly in 50% of patients. In MF
patients, the haematologic response (major, moderate and minor)
was 33% and a partial response of splenomegaly was seen in 23%
[160]. Based on this promising activity of ITF2357, different drug
dosing and drug combinations are now under investigation.
There is a single report of vorinostat in a patient with a
JAK2V617F-positive post-essential thrombocythaemia myelofi-
brosis who showed improvement in transfusion-dependent
anaemia and thrombocytopenia [161]. Modest improvement of
anaemia and reduction of transfusional support was also
serendipitously observed in a patient with PMF who had received
valproic acid for epilepsy prophylaxis [162].
Conclusions
In summary, although preliminary and sometimes conflicting,
results of available studies support abnormal epigenetic gene
regulation in MPN cells, particularly in PMF [163], as a con-
tributing mechanism to the pathophysiology of these disorders,
and maintain that epigenetics could represent a clinically rele-
vant therapeutic target [163]. Results of the first trials with
demethylating agents have been dismal, while substantial hope
that HDAC inhibitors can be more effective is supported by the
preliminary results of ITF2357 trial. It is also conceivable that
combining epigenetic therapy with other drugs might be worth-
while and more efficacious. Gene silencing because of hyperme-
thylation is involved in low response and resistance to drugs in
solid cancers [164], and re-activation of silenced gene following
decitabine was shown able to overcome resistance both in vitro
and in preclinical models [165, 166]; results of a recent dose-
finding trial of decitabine with carboplatin in solid tumours hold
much clinical promise. Therefore, one could imagine the oppor-
tunity to associate epigenetic therapy either with cytotoxic drugs
(hydroxyurea) or with the novel, specific JAK2 inhibitors [163,
167]. The coming years will surely witness great interest and
efforts in developing effective, targeted therapy against the long-
neglected MPNs.
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